RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2019-11-21
Target enrollment:
Participant gender:
Summary
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a
dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to
subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase
2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in
combination to treat subjects with metastatic pancreatic cancer as first line therapy.